AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01759238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg
Study NCT01759238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: (conventional or intensity-modulated and image-guided radiotherapy)
Study NCT03618810 — intervention group
Intervention type: DRUG
Intervention: PEGCSF first level prophylactic use
Description: 6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
Study NCT03618810 — intervention group
Intervention type: DRUG
Intervention: PEGCSF second level prophylactic use
Description: 6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
Study NCT03644615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfluness and usual care
Description: Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
Study NCT03644615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: No intervention on the patients
Study NCT02667444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically once daily
Study NCT02667444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically one daily
Study NCT02004743 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD.
Study NCT02004743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD
Study NCT03086824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance-guided focused ultrasound
Study NCT00999973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C 0.02%
Study NCT05040100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Mediastinum Model
Description: The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
Study NCT01167634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit contract with a 1:1 match
Description: Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
Study NCT01167634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit contract with a 2:1 match
Description: Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
Study NCT01167634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract with no match
Description: Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
Study NCT00574223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
Description: subcutaneous injections at 8 visits
Study NCT00574223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: House dust mite allergen extract in combination with CYT003-QbG10-placebo
Description: subcutaneous injections at 8 visits
Study NCT00939406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalospine
Description: Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone
Description: The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin or Levofloxacin
Description: The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Piperacillin-tazobactam
Description: The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline
Description: The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-clavulanate
Description: The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard course macrolide
Description: Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Extended course macrolide
Description: Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No systemic corticosteroid
Description: Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fixed-duration Hydrocortisone
Description: 50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Shock-dependent hydrocortisone
Description: 50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fixed-duration higher dose Hydrocortisone
Description: 100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No antiviral agent for influenza
Description: No antiviral agent intended to be active against influenza infection is to be administered
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Five-days oseltamivir
Description: Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ten-days oseltamivir
Description: Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No antiviral agent for COVID-19
Description: No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir / Ritonavir
Description: Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine + lopinavir/ritonavir
Description: Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No immune modulation for COVID-19
Description: No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a
Description: IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anakinra
Description: A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sarilumab
Description: Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed.
Study NCT02592681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
Study NCT02592681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupressure
Description: The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min.
Study NCT02592681 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control acupuncture
Description: The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
Study NCT04225000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
Study NCT04225000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Group
Description: Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.
Study NCT04759950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Physical Activity Program
Description: The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
Study NCT04759950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program
Description: This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local standard venous thromboprophylaxis
Description: Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Therapeutic dose anticoagulation
Description: Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional low dose thromboprophylaxis
Description: Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intermediate dose thromboprophylaxis
Description: Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Continuation of therapeutic dose anticoagulation
Description: Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No immunoglobulin
Description: No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Study NCT02735707 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent plasma
Description: Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Study NCT02735707 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Delayed administration of convalescent plasma
Description: Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No vitamin C
Description: No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin C
Description: Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed.
Study NCT04759950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
Study NCT04759950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
Study NCT00999973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01614574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: 60 U/kg every other week intravenous infusion
Study NCT02894320 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral observation
Study NCT03915119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GFT AI training
Description: navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
Study NCT02875561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopet Ultrasonic Aspirator
Description: To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation